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Abstract  
Virtual screening is used in biomedical research to predict and/or rank the binding affinity of a 
large set of small organic molecules to protein receptor targets. This report shows the 
development and evaluation of a novel yet straightforward attempt to improve this ranking in 
receptor-based molecular docking using a receptor-decoy strategy. This strategy includes 
defining a decoy binding site on the receptor and adjusting the ranking of the true binding-site 
screen based on the decoy-site screen.  The results show that by docking against a receptor-decoy 
site with Autodock Vina, improved Receiver Operator Characteristic Enrichment (ROCE) was 
achieved for five out of fifteen receptor targets investigated, when up to 15% of a decoy site rank 
list was considered.  No improved enrichment was seen for seven targets, while for three targets 
the ROCE was reduced. The extent to which this strategy can effectively improve ligand 
prediction is dependent on the target receptor investigated. 
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Introduction 
Virtual screening is a widely used technique in the field of medicinal chemistry to identify lead 
compounds from a diverse library that can bind to a receptor. The receptor based virtual 
screening approach involves a process called molecular docking which employs an algorithm 
that docks each molecule from a library into the binding site in order to predict a binding energy 
or a binding score [1]. In recent years, a number of successful virtual screening based studies 
have been conducted as described for example in the recent review by Lavecchia et al [2]. 
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Although docking provides an efficient and cost effective way to assess interactions between 
molecules such as proteins and ligands on a large-scale, the accuracy, as defined by the ability to 
predict strong binding ligands, is limited. This is largely due to the limitation of scoring 
functions used in the software to calculate binding energies, and therefore their ability to identify 
true positives from a database composed of known ligands and decoys that is typically used in 
evaluations of virtual screening [3, 4]. The accuracy of the screening method can be assessed 
quantitatively through calculation of the robust metric known as Receiver Operator 
Characteristic Enrichment (ROCE) [5]. An ROCE factor is obtained as the true positive rate 
divided by the false positive rate, thus ROCE factors much larger than 1.0 are desirable to 
establish that the docking algorithm can distinguish active compounds from decoys.  
 
Several software for molecular docking are available [6] and have been evaluated [7, 8].  
Furthermore, methods to increase the accuracy of virtual screening have been suggested, for 
example considering receptor flexibility to reduce the numbers of false positive molecules [9], 
consensus docking to predict correct binding pose [10], and a consensus virtual screening 
method that combined the rank lists of ligands from different algorithms [11]. However, these 
improved methods can still result in a low number of correct predictions for some receptors [11]. 
In the work described here the novel strategy of using receptor decoy sites was developed and 
evaluated for the first time together with the docking software AutoDock Vina [12]. This 
involved performing virtual screening against a non-binding (receptor-decoy) site on the same 
protein target, and developing a way to re-rank the screening results, thus enabling a comparison 
of ROCE factors before and after the application of receptor-decoy screening in order to evaluate 
the novel strategy.  
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Materials and Methods 
Ligand and decoy sets for fifteen target proteins were downloaded from the Database of Useful 
Decoys [3]. The complexes were selected from several different protein categories in the 
database such as hormone receptors, kinases, proteases and other enzymes to represent a wide 
range of targets, including ten targets which had previously been evaluated [11]. Virtual 
screening for all fifteen targets was performed using Autodock Vina version 1.1.1 with the 
default parameters [12]. The FTMap binding site prediction server [16] was used to help define 
the decoy site for docking. The FTMap server identifies binding hot-spots by computational 
solvent mapping whereby 16 different molecular probes are docked onto the protein surface to 
locate favorable binding regions [16].  The decoy site was chosen based on the following criteria: 
1) contains no binding hotspot predicted by FTMap, 2) it appears structurally different to the 
actual binding site and 3) it does not form an obvious binding cavity but is at a flat region on the 
exterior surface of the protein. The search space for docking was defined via a grid box manually 
specified with Autodock Tools [15] around the binding or decoy site. A grid spacing of 0.375 Å 
was used to determine the box dimensions. The box dimensions remained the same for binding 
site and decoy site docking. Adjusted rank lists were generated from the binding site list by 
considering molecules that were in the top 10%, 15%, 20%, 30% and 50% of the decoy site list, 
and adjusting the rank of the binding site list using the following formula: 
 
ܣ݆݀ݑݏݐ݁݀	ݎܽ݊݇ = (ܤ݅݊݀݅݊݃	ݏ݅ݐ݁	ݎܽ݊݇ − ܦ݁ܿ݋ݕ	ݏ݅ݐ݁	ݎܽ݊݇) + 	ܶ݋ݐ݈ܽ	݊݋. ݋݂	݈݅݃ܽ݊݀ݏ	݅݊	݈݅ݏݐ 
 
The fraction of decoy-site docking results was varied in order to find a cut-off where maximum 
enrichment is achieved. The numbers of active ligands in the database were then used to 
calculate the ROC Enrichment (ROCE) factors at 1% and 2% of the number of molecules. The 
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ROCEx% was calculated as the fraction of true positives divided by the fraction of false positives 
at x% of the ligand/decoy database according to the equation: 
 
ܴܱܥܧ௫% = ௔݂௖௧௜௩௘௦1 − ( ௗܰ௘௖௢௬௦ − ௜ܰ௡௔௖௧௜௩௘௦)
ௗܰ௘௖௢௬௦
 
Where factives = (number of actives at x%) / (number of all actives), 
Ndecoys = the total number of inactive decoys, 
Ninactives = the number of decoys chosen at x% of the ligand/decoy database. 
 
Binding site and decoy sites were analysed post-docking with the KVFinder Cavity Detection 
PyMol Plugin [14] to provide a quantitative description of the two sites. The software enables 
comparison and characterisation of protein binding sites by the number, area and volume of 
cavities in a specified search space. The default parameters were used for all fifteen targets 
which included a probe in size of 1.4Å, probe out size of 4.0Å and a step size of 0.6Å. The 
minimum cavity volume was set at 5.0Å. The binding site search space was set around the 
position of the actual ligand molecule obtained from the Protein Data Bank, and the decoy site 
search space was set using a docked molecule from the decoy site screening. 
 
Results and discussion 
High predicted binding affinities between a ligand and a receptor may not always correspond 
with the best binding molecules for the target site investigated [6, 13]. In virtual screening this is 
reflected by low enrichment factors which indicate that many of the highest ranked molecules 
may be false positive predictions [5]. In this study, the level of Receiver Operator Characteristic 
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Enrichment (ROCE) was determined at fractions of 1% and 2% of the dataset of ligand/decoy 
molecules obtained from the Database of useful Decoys [3]. Docking against a non-binding 
‘decoy’ site on the same receptor (fig. 1) was carried out using the software Autodock Vina that 
lead to a ranking of molecules different from the ranking for the true binding site. The predicted 
binding energies among top molecules for the decoy site were less negative than for binding 
sites, indicating a lower degree of binding to the decoy site. The ranking for the true binding site 
was adjusted by considering a varied fraction of the rank list produced from the decoy site from 
0% (no correction) to 50% (table 1 and 2).  
 
Figure 1. (a) Acetycholine esterase (Ache) receptor with binding site shown in red and decoy 
site in blue. (b) Detailed view of Ache binding site. (c) Detailed view of Ache decoy site. 
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The results show a considerable variation between the fifteen targets investigated confirming the 
general consensus that virtual screening accuracy is highly dependent on the target (table 1 and 
2). Overall, the majority of targets did not show any improvement in enrichment at the top 1% or 
2% of the list after applying the receptor decoy method.  Five targets (Comt, Ache, CDK2, HIVrt 
and Pparg) show improved ROCE factors compared to those obtained in the previous study [11], 
(see footnotes in table 1 and 2) when considering at least the top 15% of the decoy site list. 
Beyond 15% the enrichment for all targets (except HIVrt and Parp) either remained constant or 
dropped to a lower value. 
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Table 1. ROCE at 1% of the binding site list considering top x% of the decoy site list. 
 Top % of decoy site list 
Target 0 10 15 20 30 50 
Comt 33.41 39.0 39.0 39.0 39.0 39.0 
AchE 1.01 1.0 3.0 3.0 2.0 3.03 
CDK2 14.31 23.6 29.7 23.6 29.7 14.3 
HIVrt 9.41 13.1 13.1 9.0 13.1 18.0 
Pparg 58.01 99.0 84.0 84.0 84.0 84.0 
FGFR1 0.0 0.0 0.9 0.9 0.9 0.9 
InhA 14.6 5.3 5.3 5.3 2.5 0.0 
PR 0.0 0.0  0.0 0.0 0.0 4.0 
RXRa 212.4 212.4 212.4 88.5 47.2 88.5 
VEGFr2 10.2 2.9 2.9 2.9 1.4 1.4 
MR 178.3 178.3 71.3 71.3 71.3 71.3 
Hsp90 0.0 0.0 0.0 0.0 0.0 0.0 
AmpC 0.0 0.0 0.0 0.0 0.0 0.0 
Trypsin 5.0 5.0 5.0 5.0 5.0 5.0 
Parp 7.1 7.1 7.1 7.1 7.1 11.9 
 
1Results taken from ref [11]. 
 
 
  
 9
Table 2. ROCE at 2% of the binding site list considering top x% of the decoy site list. 
 Top % of decoy site list 
Target 0 10 15 20 30 50 
Comt 10.41 11.2 11.2 11.2 11.2 11.2 
AchE 1.51 2.0 2.0 1.5 2.0 1.5 
CDK2 13.31 15.7 15.7 15.7 11.9 5.8 
HIVrt 8.81 9.0 9.0 7.2 7.2 11.0 
Pparg 35.81 58.0 54.0 58.0 50.0 44.0 
FGFR1 0.6 0.4 0.4 0.4 0.4 0.4 
InhA 12.4 3.1 3.1 2.5 1.2 0.0 
PR 0.0 0.0  0.0 0.0 1.9 4.0 
RXRa 70.8 97.4 70.8 40.5 17.7 23.6 
VEGFr2 5.3 1.4 2.1 2.1 2.9 1.4 
MR 62.4 42.8 29.7 20.4 20.4 3.6 
Hsp90 0.0 0.0 0.0 0.0 0.0 4.5 
AmpC 0.0 0.0 0.0 0.0 0.0 0.0 
Trypsin 5.0 5.0 5.0 5.0 5.0 5.0 
Parp 5.1 3.2 7.1 7.1 7.1 9.4 
 
1Results taken from ref [11]. 
 
The rationale behind the receptor decoy strategy was that the number of false positive binders 
could be reduced by determining molecules, which have a tendency to bind non-specifically to 
molecular surfaces that are different to the binding site. As a result a higher number of active 
ligands would remain after adjusting the rank list for the true binding site with the rank list for 
the decoy site. However, the results show that this approach is unlikely to help in the 
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identification and selection of molecules for experimental testing as a higher number of true 
positives were recalled for only five targets. The extent of enrichment achieved for the top 1% 
and 2% differed for all targets due to properties that determine the binding interactions between 
amino acid residues of the target and the ligand-decoy dataset used for docking. The optimum 
cut-off for maximum enrichment at the top 1% of a binding site list was obtained when 
considering 15% of the decoy list (table 1), and 10% for the top 2% of the binding site list (table 
2). This shows that the ranking of molecules with regards to binding to the decoy sites is 
meaningless for lower ranks.  
 
The largest improvement in enrichment was achieved with the targets CDK2 and Pparg. For the 
targets PR, Hsp90 and ampC the ROCE at 1% and 2% remained at zero until considering at least 
30% of molecules in the decoy list, indicating that true and false ligands cannot be distinguished 
by the Autodock Vina docking algorithm. Cavity analyses of the binding site and decoy site 
(table 3) using the software KVFinder  [14] shows that the total number, volume and area of the 
cavities found in the decoy site were smaller in comparison to the binding site for all targets 
except HIVrt and trypsin. This confirms that the shapes of the two sites are very different, 
although this does not prevent false positive molecules binding with high affinity.    
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Table 3. Cavity analysis of binding sites and decoy sites for all targets using KVFinder [14]. 
 Binding site Cavities Decoy site cavities 
Receptor Number  Total Volume 
(Å3 ) 
Total Area 
(Å2 ) 
Number Total Volume 
(Å3 ) 
Total Area 
(Å2 ) 
Comt 1 29.8 45.7 1 12.3 20.3 
AchE 3 249.3 333.8 2 85.5 124.9 
CDK2 4 134.0 178.3 1 10.6 15.8 
HIVrt 5 92.1 138.7 1 241.3 240.1 
Pparg 2 394.4 414.8 1 8.6 14.4 
FGFR1 2 49.0 70.2 1 21.0 30.6 
InhA 2 1119.7 834.8 1 6.0 10.1 
PR 2 21.4 35.0 1 18.1 28.4 
RXRa 1 57.5 72.0 1 21.0 30.2 
Vegfr2 5 129.3 193.0 4 117.4 168.0 
MR 2 54.4 78.1 1 23.5 35.6 
Hsp90 4 166.8 233.7 2 30.0 46.1 
ampC 3 100.8 121.3 1 5.8 9.7 
trypsin 1 9.7 14.8 3 79.9 121.8 
Parp 1 538.3 482.4 1 9.9 16.6 
 
The targets Inha, MR and VEGFr2 show a significant decrease in ROCE indicating this strategy 
makes the retrieval of active ligands in the top ranks worse for these targets. The actual binding 
site for VEGFr2 appears to be non-specific, open and flat, therefore binds molecules which also 
bind easily to the decoy site, resulting in a high proportion of active molecules at the top of the 
decoy list. However, the Inha binding site is a small, deep pocket with a total cavity area of 
838.4Å2 which appears not to be easily surface accessible, so it is expected that this receptor only 
binds ligands which are complementary in shape. Although, this was not seen as a higher number 
of active ligands were found in the top 1% of the decoy site list compared to the binding site list. 
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Thus, when the re-ranking formula to generate the adjusted list is applied, the binding site list is 
re-ordered such that the active ligands do not appear in the top positions. This highlights the 
shortcoming that if applying this strategy to a virtual screening experiment where active 
molecules are not known, it cannot be guaranteed that any improved prediction accuracy will 
result.  
 
Conclusion 
The novel development and evaluation of docking with a decoy binding site shows that improved 
prediction of active ligands could not be achieved in general. It should be noted that the 
ligand/decoy dataset used for this evaluation is especially challenging as decoys physico-
chemical similar to ligands were chosen [3]. The choice of appropriate decoy binding sites is 
critical for the success of this method. Choosing an obviously unfavorable site, such as a flat 
molecular surface, reduces the docking scores overall and thus the potential to discriminate 
between ligands and decoys, while on the other hand the choice of an alternative binding cavity 
might cause a novel mode of specific binding that does not help to eliminate the false postives 
for the true binding site. The question, how to define a decoy binding site, such that false positive 
predictions for the real binding site are removed must remain open and is put forward to the 
academic community. Further work addressing the re-ranking of predicted ligands may also lead 
to improvements.  
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Comt: Catechol O-methyltransferase; AchE: Acetycholine Esterase; CDK2: Cyclin Dependent 
Kinase 2; HIVrt: HIV reverse transcriptase; Pparg: Peroxisome proliferator activated receptor 
gamma; FGFR1: Fibroblast Growth Factor Receptor kinase; InhA: Enoyl ACP reductase; PR: 
Progesterone Receptor, RXRa: Retinoic X Receptor alpha; VEGFr2: Vascular Endothelial 
Growth Factor Receptor kinase; MR: Mineralocorticoid Receptor; Hsp90: Heat shock protein 90; 
ampC: ampicillin class C; parp: poly (ADP-ribose) polymerase; ROCE: Receiver Operator 
Characteristic Enrichment. 
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